BioNTech Results Presentation Deck
Acquisition of Kite's Solid Tumor TCR-T cell platform and related assets
Transaction overview:
On July 19, BioN Tech announced an asset purchase agreement with Kite to acquire its Neoantigen
TCR Cell Therapy R&D Platform and cGMP manufacturing facility in the U.S.
Transaction closed on August 4, 2021
What we gain:
Leased U.S. clinical-stage cell therapy manufacturing facility in Gaithersburg, Maryland
Brings more than 50 highly trained cell & gene therapy scientists and production experts
Personalized Neo-antigen TCR program
Library of other preclinical TCR assets
●
40
●
●
Strategic rationale:
✓ Add turn-key U.S. cell therapy facility to complement existing facility in Idar-Oberstein, Germany
✓ Enable expansion of U.S. clinical supply of CARVac and other BioNTech cell therapies.
✓ Strengthen U.S. team with highly skilled TCR scientists and manufacturing workforce
✓ Expand BioNTech's proprietary cell therapy pipeline and capabilities
BIONTECHView entire presentation